Will Sovaldi and Harvoni pass the first gateway for insurance benefit?
The health insurance benefit evaluation scheme of the Gilead’s hepatitis C treatments, Sovaldi(sofosbuvir) and Harvoni(sofosbuvir, ledipasvir) will finally be proposed at the Drug Benefit Deliberation Committee, Health Insurance Review & Assessment Service(HIRA), today(24th).
It has been 5 mont...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
